Emcure Pharmaceuticals Ltd (EMCURE)
₹1,871.80
Mkt cap
₹35,510 Cr
P/E ratio
34.50
P/B
7.17
Div yield
0.19%
ROE
20.10%
ROCE
24.00%
EPS (TTM)
₹54.26
Book value
₹261
52W range
1,307–2,101
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]
NSE EMCUREBSE 544210
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−10.90% from high₹1,872
₹1,307+43.27% from low₹2,101
Current
₹1,871.80
Prev close
₹1,865.00
Day
+0.36%
Price performance
1D
+0.05%
1W
+5.40%
1M
−4.75%
3M
−2.35%
6M
+7.87%
1Y
+34.73%
YTD
+30.81%
Financials
Revenue, profit & margin
P/E ratio
34.5×
EMCURE is 0% above the sector median of 34.4×
EMCURE34.5×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,556 | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 | |
| Expenses | 1,261 | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 | |
| Operating Profit | 296 | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 | |
| OPM % | 19% | 20% | 18% | 18% | 19% | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% | |
| Other Income | 15 | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 | |
| Interest | 52 | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 | |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 | |
| Profit before tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 | |
| Tax % | 26% | 26% | 30% | 27% | 26% | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% | |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 | |
| EPS in Rs | 7.21 | 7.69 | 6.27 | 6.36 | 7.95 | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | 15.50 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.54% · closed higher next day 3 of last 9
| Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 13 Aug '24◦ | 8 Nov '24 | 6 Feb '25◦ | 22 May '25◦ | 7 Aug '25 | 11 Nov '25 | 4 Feb '26 | 5 May '26◦ | 6 Aug '26 |
| Earnings day | +0.54% | −3.19% | −5.64% | +9.99% | −1.52% | −3.99% | +1.91% | −1.82% | −1.14% |
| +1 day | +1.78% | −0.37% | −8.73% | +20.18% | −2.57% | −6.25% | −1.59% | −1.51% | +0.99% |
| +5 days | +9.92% | −9.35% | −22.61% | +13.89% | +2.29% | −4.63% | −0.49% | −1.97% | +2.58% |
| +15 days | +13.63% | −4.27% | −25.58% | +16.59% | −2.86% | −2.45% | −5.01% | +2.07% | −4.11% |
| +30 days | +15.81% | −1.33% | −21.69% | +7.25% | −7.40% | −0.01% | −2.35% | +3.72% | +2.29% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202677.82%Promoter
Promoters77.82%0.01
FIIs4.94%0.07
DIIs8.49%0.03
Public8.75%0.09
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Emcure Pharma | ₹1,871.80 | 34.47 | 35,510 | 0.19% | 292 | +40.45% | 2,580 | +22.85% | 24.02% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports2
Concall transcripts21
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 14 OctBoard Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2026 14 Oct - Board meeting on November 3, 2026 to approve Q2 and half-year unaudited results; trading window closed till November 5.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026Announcement under Regulation 30 (LODR)-Scheme of Arrangement 12 Oct - Board approved amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals into Emcure, subject to approvals.Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 2 Oct - Income-tax Department imposed Rs. 57.74 crore penalty for FY2014-15 to FY2020-21; company may appeal.